Physician profile
Daniel B Hurley
NPI 1124007828
$2,710.98
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $476 · 2021: $1,035 · 2022: $207 · 2023: $68.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $649.28 | 2019-2023 | |
| Genzyme Corporation | $347.52 | 2019-2022 | |
| Csl Behring | $298.73 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $281.72 | 2019-2022 | |
| Medtronic USA, INC. | $257.81 | 2019-2020 | |
| Aerin Medical INC. | $235.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $210.24 | 2019-2023 | Nucala |
| Intersect Ent, INC. | $82.32 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $81.15 | 2019-2021 | |
| Kaleo, INC. | $67.43 | 2021-2023 | Auvi-Q |
| Stryker Corporation | $47.95 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.81 | 2020-2021 | |
| Shire North American Group INC | $27.12 | 2019 | |
| Smith+Nephew, INC. | $19.44 | 2019 | |
| Pharming Healthcare, INC. | $17.52 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.04 | 2021 | |
| Aimmune Therapeutics, INC. | $13.54 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.